NASD · Healthcare · Biotechnology · USA
CorMedix Inc is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.
CorMedix Inc is a biopharmaceutical company that develops treatments for severe medical conditions. The company markets DefenCath, a solution used in central venous catheters for hemodialysis patients to prevent bloodstream infections, and following its acquisition of Melinta Therapeutics, also sells infectious disease medications and a cardiovascular product distributed through hospitals and clinics.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the CorMedix Inc stock.
Undervalued: intrinsic value $22.19 per share, market price $5.70, margin of safety 74.3% (as of 2026-10-30).
Discounting its cash flows at 10.0% (average of 2 methods) values the shares at $22.19; the price of $5.70 is 74% below that value, and 69% of that value comes from beyond year five.
Leak Score: 83/100 on 11 of 12 signals (Strong Leak).
17 more funds hold it; the full list is part of the paid plan.
CRMD is undervalued (as of the 2026-10-30 close). Discounting its cash flows at 10.0% (average of 2 methods) values the shares at $22.19; the price of $5.70 is 74% below that value, and 69% of that value comes from beyond year five.
$22.19 per share (as of the 2026-10-30 close), against a market price of $5.70. That is a margin of safety of 74.3%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
83 out of 100, which we rate "Strong Leak", on 11 of 12 value investing signals.